SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    James R. Burton, Jacqueline G. O’Leary, Elizabeth C. Verna, Varun Saxena, Jennifer L. Dodge, Richard T. Stravitz, Joshua Levitsky, James F. Trotter, Gregory T. Everson, Robert S. Brown, Norah A. Terrault, A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy, Journal of Hepatology, 2014, 61, 3, 508

    CrossRef

  2. 2
    Eva Van den Eynde, Elena Ferrer, Daniel Podzamczer, Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir, AIDS, 2014, 28, 10, 1538

    CrossRef

  3. 3
    V. Virlogeux, P. Pradat, F. Bailly, G. Funingana, F. Gonçalves, M. Maynard, K. Hartig-Lavie, M. Amiri, F. Zoulim, Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score, Journal of Viral Hepatitis, 2014, 21, 9
  4. 4
    Véronique Loustaud-Ratti, Annick Rousseau, Paul Carrier, Chanlina Vong, Tristan Chambaraud, Jérémie Jacques, Marilyne Debette-Gratien, Denis Sautereau, Marie Essig, eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?, Liver International, 2014, 34, 10
  5. 5
    Patrizia Burra, Kryssia I. Rodríguez-Castro, Francesco Marchini, Luciana Bonfante, Lucrezia Furian, Alberto Ferrarese, Alberto Zanetto, Giacomo Germani, Francesco Paolo Russo, Marco Senzolo, Hepatitis C virus infection in end-stage renal disease and kidney transplantation, Transplant International, 2014, 27, 9
  6. 6
    Massimo Tempestilli, Raffaella Lionetti, Gianpiero D'Offizi, Marzia Montalbano, Andrea Giaffreda, Simone Fazio, Leopoldo P. Pucillo, Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir, Hepatology, 2014, 60, 3
  7. 7
    Kevin Humphries, Jama M. Darling, A. Sidney Barritt, Membranoproliferative Glomerulonephritis, Type II Cryoglobulinemia and Triple Therapy for Hepatitis C: A Case Series and Review of the Literature, Digestive Diseases and Sciences, 2014, 59, 8, 2007

    CrossRef

  8. 8
    Sarah Zimner-Rapuch, Nicolas Janus, Gilbert Deray, Vincent Launay-Vacher, New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment, Drugs, 2014, 74, 12, 1307

    CrossRef

  9. 9
    André-Jean Rémy, Bruno Lesgourgues, Bernard Nalet, Xavier Causse, Jean Henrion, Jacques Denis, Ramuntxo Arotçarena, Hervé Hagège, Alexandre Pariente, Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C, European Journal of Gastroenterology & Hepatology, 2014, 26, 9, 996

    CrossRef

  10. 10
    Umberto Vespasiani-Gentilucci, Paolo Gallo, Antonio Picardi, Renal impairment and anemia during triple therapy, Journal of Hepatology, 2014, 60, 5, 1099

    CrossRef

  11. 11
    Véronique Loustaud-Ratti, Paul Carrier, Chanlina Vong, Marie Essig, Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir, Hepatology, 2014, 59, 6
  12. 12
    Zulane Veiga, Gustavo H.S. Pereira, Flávia F. Fernandes, Daniela M. Mariz, João L. Pereira, Reply to, European Journal of Gastroenterology & Hepatology, 2014, 26, 6, 687

    CrossRef

  13. 13
    Manuel Romero-Gómez, Marina Berenguer, Esther Molina, Jose-Luis Calleja, Reply to: “Renal impairment and anemia during triple therapy”, Journal of Hepatology, 2014, 60, 5, 1100

    CrossRef

  14. 14
    Harald Farnik, Nerea Ferreirós, Sandra Labocha, Gerd Geisslinger, Stefan Zeuzem, Christoph Sarrazin, Johannes Vermehren, Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection, Scandinavian Journal of Gastroenterology, 2014, 1

    CrossRef

  15. 15
    Tetsuo Takehara, Simeprevir for the treatment of chronic hepatitis C genotype 1 infection, Expert Review of Anti-infective Therapy, 2014, 12, 8, 909

    CrossRef

  16. 16
    A. Kyvernitakis, E. Jabbour, H. A. Torres, Sustained Virologic Response After 6 Weeks of Therapy With a First-Generation Hepatitis C Virus Protease Inhibitor, Clinical Infectious Diseases, 2014, 58, 9, 1342

    CrossRef

  17. 17
    Amedeo De Nicolò, Lucio Boglione, Alessia Ciancio, Jessica Cusato, Silvia Strona, Chiara Simona Cardellino, Adnan Mohamed Abdi, Giuseppe Cariti, Giulia Troshina, Gian Paolo Caviglia, Antonina Smedile, Mario Rizzetto, Giovanni Di Perri, Antonio D’Avolio, Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner, Antiviral Research, 2014, 109, 7

    CrossRef

  18. 18
    T. Oze, N. Hiramatsu, T. Yakushijin, R. Yamada, N. Harada, N. Morishita, M. Oshita, E. Mita, T. Ito, Y. Inui, M. Inada, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, T. Miyagi, Y. Yoshida, T. Tatsumi, A. Kasahara, N. Hayashi, T. Takehara, The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1, Journal of Viral Hepatitis, 2014, 21, 12